课题基金 / 基金详情

Yogurt beverages as a vehicle to deliver high dose probiotics

Yogurt beverages as a vehicle to deliver high dose probiotics
酸奶饮料作为提供高剂量益生菌的载体
批准号:
7937876
负责人:
DANIEL J MERENSTEIN
金额:
$21.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2014-03-31

项目摘要

项目成果

DANIEL J MERENSTEIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Probiotics are live microorganisms that, when administered in sufficient amounts, may improve health. Often, probiotics are ingested as supplements in powder, pill or liquid forms, designed specifically for medicinal benefit. Yogurt can be an effective delivery vehicle for probiotics, but generally yogurts available in the United States are not formulated with attention to optimal probiotic strains or dose. Yogurt is also an attractive delivery agent because of its popularity with parents and children, likely improving compliance. We propose to evaluate yogurt formulated with a probiotic strain at a dose that results in recovery in stools. The long-term goal of this project is to demonstrate that a probiotic-containing yogurt beverage can be used successfully as a vehicle for delivering health-enhancing probiotics to children. The specific goals of this study are to determine if a yogurt drink containing Bifidobacterium lactis (Bb-12) at a minimum 1010 colony forming units (CFU)/per serving can prevent antibiotic-associated diarrhea (AAD). We have three specific aims to accomplish these goals. Aim #1: To determine if consumption of a yogurt drink containing a high dose of probiotics decreases the incidence of antibiotic-associated diarrhea in children ages 1-3 taking a penicillin-class antibiotic compared to a matching placebo drink. Aim #2: To evaluate the feasibility of children consuming a drinkable yogurt on a regular daily basis when the children are ill. Aim #3: To determine if the supplemental Bb-12 probiotics survive the gastrointestinal tract and can be recovered from the stools of participants consuming the Bb-12 yogurt drink. This proposal is in direct response to a PA and our Aims are in consort with NCCAM's mission. NCCAM has identified areas of research needing further investigation, stating, "Use of adequately defined products and optimal dosage schedules in studies decreases the risk of failures that might discourage further research into otherwise promising modalities." Therefore, NCCAM recommends studies designed to: 1) determine active ingredients, pharmacology, bioavailability and optimal dosing; 2) identify surrogate markers; and, 3) assess study feasibility. The outcomes of these studies will form the basis for designing larger trials with an enhanced ability to detect a meaningful positive effect of the therapy under study. A readily available yogurt with high dose probiotics has the potential to positively impact the health of children around the world, as yogurt will likely be more appealing to both children and their parents for long term consumption than pharmaceutical-like probiotic preparations. Public Health Relevance: Probiotics are live microorganisms that, when administered in sufficient amounts, may improve health. Generally probiotics are ingested as supplements in powder, pill or liquid forms, designed specifically for medicinal benefit. Probiotics may be included as ingredients in fermented dairy products. A probiotic-containing yogurt beverage can potentially be used successfully as a vehicle for delivering health-enhancing probiotics to children, resulting in a functional food; that is a food providing health benefits beyond its nutritional value. Our primary aim is to see if a high dose probiotic drink can prevent antibiotic-associated diarrhea in children ages 1-3 taking a penicillin-class antibiotic. Additionally, this study will allow us to assess the feasibility of this approach to delivering probiotics in a food product and, if successful, in the future enhance other aspects of health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase II randomized controlled trial to evaluate the role of BB-12 in antibiotic-associated diarrhea and its effects on the gut microbiome
  • 批准号:
    10425501
  • 项目类别:
  • 资助金额:
    $32.7万
  • 财政年份:
    2021
  • 负责人:
    DANIEL J MERENSTEIN
  • 依托单位:
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
  • 批准号:
    10480824
  • 项目类别:
  • 资助金额:
    $28.82万
  • 财政年份:
    2018
  • 负责人:
    DANIEL J MERENSTEIN
  • 依托单位:
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
  • 批准号:
    10264947
  • 项目类别:
  • 资助金额:
    $47.2万
  • 财政年份:
    2018
  • 负责人:
    DANIEL J MERENSTEIN
  • 依托单位:
Exploratory Pilot Studies to Demonstrate Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
  • 批准号:
    10222939
  • 项目类别:
  • 资助金额:
    $43.34万
  • 财政年份:
    2018
  • 负责人:
    DANIEL J MERENSTEIN
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: